Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: National and Kapodistrian University of Athens, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Hospital Clínic de Barcelona, Ospedale Papa Giovanni XXIII, University of Tübingen, Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, Medizinische Hochschule Hannover, Isala, Université de Bordeaux, Inserm, University Medical Center of the Johannes Gutenberg University Mainz, Pfizer (United States), Université Paris-Saclay, Institut Gustave Roussy, University Hospital Zurich
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2946954076